Infectious mononucleosis (IM) is a common self-limiting febrile lymphoproliferative disease. It is caused by the Epstein-Barr virus (EBV), a member of the herpesvirus group. IM is most commonly seen in adolescents and young adults who lack antibodies to EBV. Routine tests for diagnosis of IM may be nonspecific. That is, patients infected with EBV rapidly produce heterophile antibodies, also known as Paul-Bunnell antibodies (9) ; there are also other diseases, such as serum sickness, lymphoma, hepatitis, and leukemia, in which heterophile antibodies are produced. It is essential, then, to differentially absorb test sera with guinea pig kidney (GPK) or bovine cells to increase the specificity of the test for IM. Evans and Niederman (la) evaluated an immune adherence hemagglutination assay for IM described by Lennette et al. (7) . They indicated that the immune adherence hemagglutination assay was more sensitive, gave higher titers, and was positive longer than the standard absorbed horse or sheep erythrocyte (RBC) tests in both clinical and subclinical EBV disease.
Lennette and Henle (8) indicated that 85% of classical IM cases can be rapidly and inexpensively diagnosed by using one of the rapid RBC-sensitized tests. They also state that these tests should not be used to monitor the course of the disease, as there is little relationship between the severity of the disease and the titer of heterophile antibody.
Most laboratories use a screening test for IM which is based on the observation that horse RBCs are agglutinated by the Paul-Bunnell antibody. Even in these rapid tests, the sera must be absorbed with GPK and bovine erythrocytes (BRBCs). Some patients may not produce heterophile antibodies or may produce them late (8 Monospot results, two false-positive and six false-negative Monolatex results, and eight false-positive and one falsenegative Immunoscan-IM result. One patient was thought to have chronic mononucleosis on the basis of both clinical and laboratory evidence. Both LA kits were positive and the Monospot result was negative for this serum sample. A total of 14 uniformly positive and 16 negative sera were chosen for complete EBV antibody analysis. Sera were analyzed by using the complete EBV antibody panel. The EBV results indicated complete agreement with the screening tests for these sera. That is, the sera that were positive in all three screening tests showed EBV profiles consistent with acute infectious mononucleosis and the uniformly negative sera showed a pattern consistent with either old infection or no exposure to EBV. EBV antibody profiles are particularly useful when there is a delayed or absent heterophile antibody response. The first EBV antibody to appear is an IgM antibody to VCA within a few days to a few weeks after infection. Shortly thereafter, VCA-IgG antibodies appear and may remain for life (5) . VCA-IgM antibodies disappear within 2 months. The presence of antibodies to EA and the absence of antibodies to EBNA signal an acute infection. The most useful single diagnostic test is that for EBV-VCA-IgM antibodies. Routine testing for specific EBV antibodies may not be practical for most clinical laboratories, although the immunofluorescent reagents are commercially available.
In this report, two LA tests and one widely used differential slide test (Monospot) were compared. A total of 220 selected patient sera were tested, approximately 50% positive and 50% negative. Because of this selection process, the true prevalence of IM is not reflected in this study. Accordingly, the calculated predictive values for each test kit are invalid unless the anticipated prevalence in the population to be tested is 50%. Also, for the initial test evaluation, Monospot was arbitrarily specified as the reference standard and the sensitivity and specificity of the two LA products were determined from those base-line reference values.
When there was a discrepancy among the three procedures, the EBV panel was used to mediate these discrepancies. Before resolution, the Monolatex test lacked sensitivity (89.4%) and the Immunoscan-IM test lacked specificity (91.4%). When the discrepant results were compared with those of the EBV antibody tests, almost 50% (5 of 11) of the initially false-negative Monolatex tests were true-negatives, signifying old infection or no infection. Five of the six false-negative Immunoscan-IM results were changed to true negatives. Specificity was increased slightly. However, Monospot was falsely positive in six instances and falsely negative in two instances when compared with the EBV profile.
Horowitz et al. (6) reported data from five individuals whose Monospot tests remained falsely positive for 4 pharyngitis and malaise. Many of the heterophile-positive patients also had lymphadenopathy. This 30-patient random sample of the test population is small. However, the results suggest that there would not be a significant number of patients whose EBV profile would change the interpretation of the screening tests when there was uniform agreement, either positive or negative, among the three test kits.
The objective of this study was to compare three commercially available kits for detection of IM-specific heterophile antibody. When all three kit results were positive for a single specimen, the only conclusion that could be drawn was that there was methodologic agreement. A positive heterophile antibody test is only one factor in the diagnosis of acute IM, and a negative test does not rule out the disease.
Similarly, when there was methodologic disagreement between tests due to differences in sensitivity and specificity, specific EBV antibody profiles were performed only to reconcile these differences, not necessarily to establish a diagnosis.
When coupled with clinical information, however, specific EBV antibody patterns can be useful in staging EBV disease.
This study indicates that any one of the three IM kits evaluated can be successfully used as a screening test for IM. The LA tests have the advantage that no differential absorption step is necessary. If there is a disadvantage, it appears that there may be some nonspecific agglutination with the Immunoscan-IM product, albeit specificity with the resolved discrepant specimen results was >93%. There was no significant difference in sensitivity between the two LA kits when the discrepancies were resolved.
